Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital
Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…
ractigenFebruary 10, 2021